Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis - Top-Institutions - MDSpire

Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis

  • By

  • Sharlene Dong

  • Rahul Banerjee

  • Adeel M. Khan

  • Mengru Wang

  • Xiaoliang Wang

  • Anosheh Afghahi

  • Aimaz Afrough

  • Murali Janakiram

  • Bo Wang

  • Andrew J. Cowan

  • Adam S. Sperling

  • Larry D. Anderson

  • S. Vincent Rajkumar

  • Gurbakhash Kaur

  • March 28, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

  • #4

    University of Arkansas for Medical Sciences (UAMS)
    University of Arkansas for Medical Sciences (UAMS)

    Little Rock, AR

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

Original Source(s)

Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis

  • by Sharlene Dong, Rahul Banerjee, Adeel M. Khan, Mengru Wang, Xiaoliang Wang, Anosheh Afghahi, Aimaz Afrough, Murali Janakiram, Bo Wang, Andrew J. Cowan, Adam S. Sperling, Larry D. Anderson, S. Vincent Rajkumar, Gurbakhash Kaur

  • March 28, 2025

Related Content

Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside